Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care
By
Wayne Kuznar
NCCN Guidelines
,
Policies & Guidelines
July 2011, Vol 2, No 4
Philadelphia, PA—The National Com - prehensive Cancer Network (NCCN) is an alliance of academic cancer centers in the United States that seeks to optimize decision-making and policies for improving the delivery of appropriate and effective cancer care.
Read More
Benefit Design Trends in Oncology Management
By
Wayne Kuznar
Oncology Benefit Edition
July 2011, Vol 2, No 4
Read More
The Role of Molecular Diagnostics in Cancer Treatment
By
Wayne Kuznar
Cancer Care
,
Personalized Medicine
July 2011, Vol 2, No 4
Philadelphia, PA—The field of oncology stands to benefit greatly from molecular diagnostic trends, according to Jane F. Barlow, MD, MPH, MBA, Vice President, Clinical Innovation, Medco Health Solutions, who offered a pharmacy benefit manager’s (PBM) perspective of the role of diagnostics, including the use of companion tests in drug development. These companion tests will represent another potential expenditure and coverage decision for PBM companies.
Read More
Payer Trends in Oncology: Challenges and Solutions
By
Wayne Kuznar
July 2011, Vol 2, No 4
Philadelphia, PA—As the cost of cancer care continues to rise, payers are struggling with solutions to curtail the cost trend while maintaining value. This was the topic of the preconference session, which opened the 2-day First Annual Conference of the Association for Value-Based Cancer Care on March 29, 2011.
Read More
Value-Based Insurance Design in Oncology
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
,
Value-Based Care
July 2011, Vol 2, No 4
Philadelphia, PA—The “one-size-fitsall” approach to current benefit designs does not recognize that health services have different levels of value; such an approach, therefore, lacks incentives for patients to adhere to diagnostic tests and treatments with proven effectiveness that may help to contain costs to various healthcare stakeholders.
Read More
AVBCC First Stakeholder Integration Conference
By
Gary M. Owens, MD
;
Burt Zweigenhaft, PhD, D.Litt
July 2011, Vol 2, No 4
In 2011 we find ourselves in the midst of a “perfect storm” as it relates to cancer care in the United States. More people are being diagnosed with cancer, more patients are living longer with cancer, and the cost of caring for cancer is rising dramatically.
Read More
Dramatic Progress in Fight against Advanced Melanoma
ASCO
,
ASCO Annual Meeting
June 2011, Vol 2, No 3
Chicago, IL—Oncologists do not engage in hyperbole. It is not in their nature. If the word “unprecedented” is used to describe a clinical outcome, it’s because something truly remarkable has occurred; such is the case in the reporting of 2 investigations of advanced melanoma at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) for the drugs vemurafenib (PLX4032) and ipilimumab (Yervoy).
Read More
The Challenge of Value-Based Care in Oncology: Improving Clinical Outcomes
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
June 2011, Vol 2, No 3
The focus on value in patient care has taken a prominent place in any discussion related to improving care delivery, but no agreement exists on what that “value” is.
Read More
Accountable Care Organizations: Implications for Oncologists
By
Rhonda Greenapple, MSPH, Reimbursement Intelligence
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
The journey for healthcare costsavings is a never-ending process. One of the newest healthcare delivery models, which is mandated for Medicare beneficiaries in the healthcare reform law, is the accountable care organization (ACO).
Read More
ASCO Calls for Open Discussions and Individualized Care for Patients with Advanced Cancer
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
Frank discussions with patients about their advanced cancer are challenging for physicians and their patients; however, avoiding such interactions is not a viable option, according to the American Society of Clinical Oncology (ASCO).
Read More
Page 314 of 330
311
312
313
314
315
316
317
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma